Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Beam Therapeutics Inc Logo

Combined Holdings of Beam Therapeutics (BEAM) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
January 20, 2022BUY22.800k0.0375%ARKG
January 18, 2022BUY75.791k0.1117%ARKG
January 6, 2022BUY42.300k0.0207%ARKK
January 5, 2022BUY18.600k0.0263%ARKG
January 5, 2022BUY14.100k0.0064%ARKK

Key Statistics

Upcoming EarningsSee Full Calendar
DateMarch 14, 2022(Est)Revenue
Expected$2.31m
Actual▫️
EPS
Expected-$1.03
Actual▫️
🕵🏼Found In🏷Last Price
ARKKARKG$63.70
⚖️Weighting🧢Market Cap
2.42%$4.34b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
135557.3
💳ARK Estimated Cost Average🌏Country
$83.56 - ARKG$84.93 - ARKK
🇺🇸United States
🎫ARK Ownership Percent
12.13%
Description
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Website
beamtx.com

Research Notes and Commentary for BEAM